myNEO
Personalized neoantigen target discovery - ImmunoEngine for personalized immunotherapies
The myNEO workflow discovers and prioritizes neoantigens for individual patients using our ImmunoEngine pipeline. The workflow is IVD-ready. Starting from tumor and matched healthy sequencing data, it analyzes variant expression and translation, predicts MHC class I and II presentation, scores CD4+ and CD8+ immunogenicity, and selects a prioritized neoantigen set. Results are reviewed in neoHUB. Selected neoantigens can proceed to myCONSTRUCT and myRNA for product design.
What myNEO delivers
The personalized workflow has a turnaround of five business days, from receipt of sequencing data to the prioritized neoantigen selection. Optional myCONSTRUCT and myRNA design can follow within one day:
- Required inputs: whole-genome and RNA sequencing of the tumor, and whole-genome sequencing of a matched healthy sample, usually blood
- Variant expression analysis
- Translation analysis
- Presentation prediction: identification of MHC-presented epitopes on both MHC class I and MHC class II molecules
- Immunogenicity prediction: identification of presented epitopes recognized by both CD4 and CD8 immune cells
- Final epitope selection: based on antigen score, clonality, functional relevance, and immune-escape likelihood
- Data visualization: web-based reporting in neoHUB for navigating complex datasets
- myCONSTRUCT: next-generation string-of-beads design (optional)
- myRNA: next-generation codon optimization (optional)
Review the prioritized set in neoHUB
neoHUB is the reporting platform for the personalized myNEO workflow. It presents variant analysis, expression data, predicted presentation and immunogenicity, and the prioritized neoantigen set so clinicians and researchers can review the output.
What is the myNEO personalized discovery workflow?
The myNEO workflow discovers and prioritizes neoantigens for individual patients. Starting from tumor and matched healthy sequencing data, it analyzes variant expression and translation, predicts MHC class I and II presentation, scores CD4+ and CD8+ immunogenicity, and selects a prioritized neoantigen set for downstream product design.
What input data does the personalized workflow need?
Three inputs are required: whole-genome and RNA sequencing of the tumor, and whole-genome sequencing of a matched healthy sample, which is usually blood.
How long does personalized neoantigen discovery take?
The personalized myNEO workflow has a turnaround time of five business days, from receipt of sequencing data to the prioritized neoantigen selection. Downstream construct design with myCONSTRUCT and codon optimization with myRNA can be delivered within one day.
What is neoHUB?
neoHUB is the web-based reporting platform for the personalized myNEO workflow, available at neohub.myneotx.com (opens in a new tab). It presents variant analysis, expression data, predicted presentation and immunogenicity, and the prioritized neoantigen set so clinicians and researchers can review and interpret the workflow output.
Can personalized discovery continue into product design?
Yes. Selected neoantigens can proceed to myCONSTRUCT for multi-epitope construct design, followed by myRNA for codon optimization of the encoding sequence, producing a synthesis-ready multi-epitope design.